Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer

Src tyrosine kinases are overexpressed in pancreatic cancers, and the oral Src inhibitor saracatinib has shown antitumor activity in preclinical models of pancreas cancer. We performed a CTEP-sponsored Phase II clinical trial of saracatinib in previously treated pancreas cancer patients, with a prim...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Arcaroli, John, Quackenbush, Kevin, Dasari, Arvind, Powell, Rebecca, McManus, Martine, Tan, Aik-Choon, Foster, Nathan R, Picus, Joel, Wright, John, Nallapareddy, Sujatha, Erlichman, Charles, Hidalgo, Manuel, Messersmith, Wells A
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Ltd 2012
Teme:
Clinical Cancer Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3544442/
https://ncbi.nlm.nih.gov/pubmed/23342270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.27
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki